Skip to content

Study on the protective mechanism of dexmedetomidine on the liver of Perioperative Diabetic Patients: a randomzied controlled trial.

Study on the protective mechanism of dexmedetomidine on the liver of Perioperative Diabetic Patients

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000033428
Enrollment
Unknown
Registered
2020-05-31
Start date
2020-06-01
Completion date
Unknown
Last updated
2020-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

protection of liver function in diabetic patients

Interventions

D group:Intravenous pump of dexmedetomidine
C group:Intravenous injection of normal saline

Sponsors

The First Affiliated Hospital of Chengdu Medical College
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 80 Years

Inclusion criteria

Inclusion criteria: Both groups of patients met the diagnostic criteria of type 2 diabetes established by who in 1999: typical symptoms of more than three, less than three, fasting blood glucose concentration >= 7.0mmol/l or a random venous plasma glucose concentration >= 11.1mmol/l or OGTT two hours after meal blood glucose concentration >= 11.1mmol/l. The above examination needs to be confirmed at least twice, and the diagnosis of diabetes can be established. The patient had a history of diabetes for more than one year.

Exclusion criteria

Exclusion criteria: 1. Severe cardiovascular and cerebrovascular diseases, cardiac function level 3 or above; 2. Severe respiratory disease, pulmonary dysfunction grade III or above; 3. Severe liver and kidney dysfunction; 4. Nerve block anesthesia, combined spinal and epidural anesthesia; 5. Patients without informed consent; 6. Patients with conduction block; 7. Right metomidine drug allergy.

Design outcomes

Primary

MeasureTime frame
SOD;MDA;ALT;AST;TG;HDL;LDL;CHOL;FFA;

Countries

China

Contacts

Public ContactDong Shuhua

The First Affiliated Hospital of Chengdu Medical College

382217690@qq.com+86 13880892273

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026